deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT02486406

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)

Sponsor: AbbVie

Conditions Chronic Hepatitis C Infection
Interventions Dasabuvir Dasabuvir mini tablet Ombitasvir mini tablet Ombitasvir/paritaprevir/ritonavir Paritaprevir mini tablet Ribavirin Ribavirin solution Ritonavir mini tablet
Updated 16 times since 2017 Last updated: Sep 7, 2021 Started: Oct 28, 2015 Primary completion: Nov 19, 2020 Completion: Nov 19, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Chronic Hepatitis C Infection and is currently completed. AbbVie leads this study, which shows 16 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Jun 2020 · 10 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Nov 2021 · 9 months · monthly snapshot~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Phase: PHASE2 → PHASE2_PHASE3

  5. Feb 2021 — Nov 2021 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Aug 2019 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting · Phase: PHASE3 → PHASE2

  10. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Berlin, Germany , Boston, United States , Brussels, Belgium , Esplugues de Llobregat, Spain , Freiburg im Breisgau, Germany , Gainesville, United States , Houston, United States , Indianapolis, United States and 10 more locations